• Biospecimen SolutionsPrecision Value & HealthCareers
    P_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGB
    • Clinical
      Trial Services
        • Overview
            • Oncology Clinical TrialsImage

              Oncology Clinical Trials


              Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

              • Rare & Orphan DiseaseImage

                Rare & Orphan Disease


                With experience built on 150+ orphan disease projects covering 80+ rare diseases, we know how to anticipate logistical and regulatory obstacles and craft bold solutions that drive rare disease development programs.

        • Global Clinical Trial Support –
            • North & South America –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Europe –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • APAC –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

        • Clinical Trial Management –
            • Study Start-up & Feasibility –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Project Management –
            • Patient Recruitment –
            • Personalized Clinical Trial Operations –
            • Biometrics –
            • Medical & Safety Monitoring –
            • Clinical Data Management –
            • Medical Writing –
        • Clinical Development Strategy –
            • Clinical Development Planning –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Biomarker Strategies –
            • Cell & Gene Therapy Strategies –
            • CDx Regulatory and Market Access –
        • Clinical Trial Design –
            • Basket & Umbrella Trials –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Biomarker Clinical Trials –
            • Master Protocol Trials –
            • Decentralized Clinical Trials
        • Biostatistics –
            • Statistical Consulting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Study Design –
            • Data Monitoring Committees –
            • CDISC Programming and Documentation –
            • eCTD Submissions –
        • Central Lab Services –
            • Clinical Specimen Kitting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Sample Processing –
            • Global Specimen Logistics and Biostorage –
            • Biospecimen Data Services –
            • Precision Lab e-Portal –
            • Virtual Sample Inventory Management –
        • Training
            • Oncology Clinical TrialsImage

              Oncology Clinical Trials


              Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

              • Rare & Orphan DiseaseImage

                Rare & Orphan Disease


                With experience built on 150+ orphan disease projects covering 80+ rare diseases, we know how to anticipate logistical and regulatory obstacles and craft bold solutions that drive rare disease development programs.

    • Lab
      Services
        • Central Lab Services –
            • Clinical Specimen Kitting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Sample Processing –
            • Global Specimen Logistics and Biostorage –
            • Biospecimen Data Services –
            • Precision Lab e-Portal –
            • Virtual Sample Inventory Management –
        • Specialty Lab Services Overview –
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

        • EU Contract Research Organization –
        • Immune Monitoring –
            • Immune Monitoring by Flow Cytometry –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • Immune Cell Phenotyping by Epiontis ID –
            • Cytokine Profiling –
            • Gene Expression Profiling –
            • ELISpot and FluoroSpot –
            • Custom Assays –
        • Flow Cytometry –
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

        • Genomics –
            • NanoString Assays –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • ddPCR –
            • qPCR –
            • NGS –
            • Fluorescence In Situ Hybridisation (FISH) / ISH –
        • Tissue & Liquid Biopsy –
            • ApoStream – CTC and Rare Cell Isolation for Liquid Biopsy
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • CTC / cfDNA / Exosome Analysis –
            • Multiplex Immunofluorescence –
            • Immunohistochemistry –
            • Fluorescence In Situ Hybridisation (FISH) / ISH
            • Pathology Services –
            • NanoString Assays
        • Bioanalytical Testing –
            • Immunogenicity Testing –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • PK Assays –
            • ADA Assays –
            • MesoScale Discovery (MSD) Assays –
            • Quanterix SIMOA –
            • ELISA
        • Cytokine Analysis –
            • ELISA –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • MesoScale Discovery (MSD) Assays
            • Luminex –
            • Quanterix SIMOA
        • Preclinical Target and Biomarker Validation –
            • Cell Based Assays –
            • Target Expression – XpressWay Profiles –
            • Tissue Cross-Reactivity –
            • Fluorescence In Situ Hybridisation (FISH) / ISH –
            • Multiplex Immunofluorescence –
            • Immunohistochemistry (IHC)
        • Biospecimens
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

    • Data
      Sciences
        • Overview
            • BiostatisticsImage

              Biostatistics


              Seasoned biostatisticians and statistical programmers support every phase of your trial, from study design for small, rare disease trials to regulatory submissions, all backed by meticulous documentation.

              • Computational BiologyImage

                Computational Biology


                Domain experts from our QuartzBio team utilize integrated and harmonized data and tailored AI solutions to drive preclinical and clinical development, including patient stratification, signature development, predictive modeling of drug response, and MOA characterization.

        • Biostatistics
        • Clinical Data Management
        • Biometrics
        • QuartzBio –
            • Biomarker Data Management –
              • BiostatisticsImage

                Biostatistics


                Seasoned biostatisticians and statistical programmers support every phase of your trial, from study design for small, rare disease trials to regulatory submissions, all backed by meticulous documentation.

            • Virtual Sample Inventory Management –
    • Diagnostics
      & CDx
        • IVD and CDx Regulatory Affairs Consulting –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • COVID-19 & Viral Panel Assays –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Biospecimens Solutions 
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Diagnostic Market Access Services –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

    • Therapeutic
      Areas
        • Overview
            • By Specialty Area
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • Oncology and Immuno-Oncology
              • Oncology Clinical Trials
            • Rare & Orphan Disease
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • Cell & Gene Therapy
              • Cell Therapy
              • Gene Therapy
              • Cell and Gene Therapy Manufacturing
            • CNS & Neuroscience
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • COVID-19
            • AutoImmune & Allergy
            • Pediatric
            • Companion Diagnostics
        • By Research Phase
        • Preclinical Development –
        • Early Phase Trials (I-IIa) –
        • Late Phase Trials (IIb-III) –
    • News &
      Insights
        • Blog –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

        • Resources –
        • Thought Leadership –
        • News –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

        • Events –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

    • About
      Us
        • Our Passion –
            • Patient RecruitmentImage

              Our Passion


              What we do, why we do it and the principles that guide us every day.

              • meet-our-peopleImage

                Meet Our People


                We are devoted professionals with deep expertise in translational science, clinical trials and data sciences.

        • Meet Our People –
        • Careers
        • Regulatory Information –
            • Patient RecruitmentImage

              Our Passion


              What we do, why we do it and the principles that guide us every day.

              • meet-our-peopleImage

                Meet Our People


                We are devoted professionals with deep expertise in translational science, clinical trials and data sciences.

    • Contact
      Us
    • Home
    • Monitoring Immune Responses in Gene Therapy Clinical Trials Using ELISpot

    Monitoring Immune Responses in Gene Therapy Clinical Trials Using ELISpot

    by Travis Harrison on August 23, 2022 — 7 minute read

    DNA Strand

    DNA Strand

    Gene Therapy and Cellular Immunity

    With two approved products currently on the market and a growing pipeline, adeno-associated virus (AAV)-based gene therapies have emerged as promising modalities for treating an array of hereditary diseases. AAV vectors offer several advantages as gene therapy vehicles, including high transduction efficiency, less immunogenicity than other viruses, and tropism for various target tissues.[1] However, due to the viral origin of the vector capsid, these therapies using AAV vectors may elicit cell-mediated immune responses that destroy transduced target cells.

    Further, pre-existing immunity may impact both efficacy and safety. An estimated 30-60% of adults carry AAV capsid-specific antibodies, with AAV5 antibodies having among the lowest prevalence.[2] Adults may also have circulating capsid-specific CD8+ and CD4+ T cells due to natural exposure to AAV. Research has shown acquired immunity from the wild-type virus, coupled with innate immunity, can decrease the efficacy of AAV gene therapy vectors.[3]

    For liver-tropic AAV vectors, there is some evidence that capsid-specific cellular immune responses, as detected by interferon-γ (IFN-γ) enzyme-linked immunospot (ELISpot) assays, can be associated with elevated plasma levels of liver enzymes.[4] In some cases, elevated liver enzymes—particularly alanine transaminase (ALT)—were also associated with a decline in transgene expression, leading to a hypothesis that ALT is released into the plasma due to the targeting of transduced cells by cytolytic immune cells.[5] Interestingly, increases in ALT can be mitigated using corticosteroids, which often also stabilize transgene expression.[6] To date, though, there has been lack of consistency in correlating cellular immunity with elevated ALT levels or declines in transgene expression, underscoring the need for reliable, robust methods for immune monitoring.

    A Method for Monitoring Cellular Immunity to AAV-based Gene Therapies

    Researchers studying AAV-based gene therapies need methods for monitoring potential eliminatory T cell responses that may affect treatment outcomes. In a recent study, Precision for Medicine helped a sponsor optimize and validate a sensitive, robust, and reliable IFN-γ ELISpot assay. The assay was designed to monitor cell-mediated immunity against an AAV5-based vector encoding human B domain-deleted factor VIII (FVIII-SQ). ELISpot was selected as the method format because it offers a broad dynamic range and is both quantitative and sensitive to single-cell level. IFN-γ, a cytokine secreted by activated T cells and natural killer (NK) cells, was chosen as the marker for cell-mediated immunity.

    Standardization of reagents and protocols is critical for establishing reproducible ELISpot results across multiple test sites and analysts.[7] While regulatory guidance on ELISpot method validation is limited, standardized assay performance evaluations and acceptance criteria are essential for reliable data interpretation.[8]

    Validating an IFN-γ ELISpot Assay for Monitoring Cell-Mediated Immune Responses

    To validate certain performance parameters for this IFN-γ ELISpot assay, human peripheral blood mononuclear cells (PBMCs) were stimulated with peptides derived from AAV5 capsid proteins and FVIII. Due to the scarcity of AAV-5 and FVIII-specific human PMBCs, cytomegalovirus phosphoprotein 65 (CMVpp65) was used as a surrogate antigen for some validation parameters. The secondary benefit of using CMVpp65 is broader application of this method as a platform technology for future gene therapy products.

    The key method performance parameters that were assessed and validated were:

    • Limit of detection (LOD), which is used to distinguish positive responses from negative ones
    • Confirmatory cutpoint (CCP), which was based on mock/antigen response ratio. The CCP would be used to adjudicate clinical trial samples in which both mock and antigen-specific response were at or above the LOD.
    • Phytohemagglutinin-L (PHA) minimum response, which served as a quality control for PBMC functionality since PHA induces polyclonal IFN-γ secretion in T cells. The PHA minimum response limit was chosen to achieve an ~1% failure rate for the assay to align with the US Food and Drug Administration (FDA) immunogenicity assay guidance.[9],[10]
    • Precision, where intra-triplicate, intra-assay, and inter-assay precision were assessed by performing three assays runs, each with three donors, and interassay precision was assessed across nine runs. These validation assessments demonstrated that the ELISpot method had acceptable precision, but direct comparison of numerical results from different runs should consider potential inter-assay variability.10
    • Linearity, which was confirmed by demonstrating that the number of responsive PBMCs plated was directly proportional to the number of spot-forming units (SFU) measured.10
    • Range of quantitation between lower limit of quantification (LLOQ) and upper limit of quantification (ULOQ), which defines where samples are quantifiable with acceptable precision.
    • Robustness, which demonstrates that the assay has substantially the same performance under different experimental conditions.
    • PBMC sample stability, which was tested by storing vials of donor PBMCs in liquid nitrogen over 18 months and periodically incubating the PBMCs under mock conditions or stimulating them with FVIII peptides to monitor response.

     

    Table 1. Summary of IFN-γ ELISpot Assay Validation

    Implementing an IFN-γ ELISpot Assay in a Gene Therapy Clinical Trial

    Once validated, the IFN-γ ELISpot assay was implemented in an AAV5-FVIII gene therapy clinical trial to monitor participants with hemophilia A for pre-existing and acquired cell-mediated immunity targeting the vector capsid or the expressed transgene. For control purposes, a donor who was not related to the study was also tested to ensure consistent assay performance. Post-treatment cellular immune responses against the AAV5 capsid were observed in 94% of participants, beginning as early as two weeks following dose administration. Most AAV5-specific responses diminished over several weeks, eventually dropping below the limit of detection. At week 52, 93% of available samples had undetectable AAV5-specific responses by ELISpot. Responses against the transgene product were limited, with one participant who was positive at baseline and at week 52, and four participants who were positive only at single time points.10

    Key Takeaways

    ELISpot has been used to detect and monitor cell-mediated immunity in numerous therapeutic areas and applications, including AAV gene therapy trials where T cell responses may affect treatment outcomes.[11],[12],[13] Here, an IFN-γ ELISpot method was validated against a set of standardized bioanalytical assessments to ensure reliable clinical data generation. Moreover, since ELISpot assays rely on the functionality of the stimulated cells, PBMC collection and cryopreservation were standardized to ensure the highest sample quality. Use of the validated IFN-γ ELISpot method in a clinical trial of AAV5-FVIII gene therapy demonstrated the utility of the assay for monitoring immune responses to viral vector capsids and expressed transgenes encoded by gene therapy vectors.

    To learn more about using validated methods for monitoring cellular immunity in AAV gene therapy trials, click here.

     

    References

    [1] Verdera HC, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: A long journey to successful gene transfer. Mol Ther 2020;28;723-746.

    [2] Stanford S, et al. Adenovirus-associated antibodies in UK cohort of hemophilia patients: a seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A. Res Pract Thromb Haemost 2019;3:261–267.

    [3] Nidetz NF, et al. Adeno-associated viral vector-mediated immune responses: Understanding barriers

    to gene delivery. Pharmacol Ther 2020;207:107453.

    [4] Mingozzi F, High KA. Overcoming the host immune response to adeno-associated virus gene delivery vectors: The race between clearance, tolerance, neutralization, and escape. Annu Rev Virol 2017; 4:511–534.

    [5] Nathwani AC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357–2365.

    [6] Ertl HCJ, High KA. Impact of AAV capsid-specific T-cell responses on design and outcome of clinical gene transfer trials with recombinant adeno-associated viral vectors: An evolving controversy. Hum Gen Ther 2017;28:328-337.

    [7] Britten CM, et al. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 2012;37:1-2.

    [8] Maecker HT, et al. Precision and linearity target for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol 2008;9:9.

    [9] Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, US Food and Drug Administration. Immunogenicity testing of therapeutic protein products — developing and validating assays for antidrug antibody detection, 2019. Available at https://www.fda.gov/regulatory-information/searchfda-guidance-documents/immunogenicity-testing-therapeutic-protein-productsdeveloping-and-validating-assays-anti-drug.

    [10] Patton KS, et al. Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-γ ELISpot method. Mol Ther Methods Clin Dev 2021;22:183-195.

    [11] Dubey S, et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Imune Defic Syndr 2007;45:20-27.

    [12] Körber N, Behrends U, Hapfelmeier A, Protzer U., Bauer T. Validation of an IFNg/IL2 FluoroSpot assay for clinical trial monitoring. J Transl Med 2016;14:175.

    [13] Banas B, et al. Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplants recipients: a multicenter, longitudinal, prospective, observational study. Transpl Int 2018;31:436-450.

     

     

     

     

     

    Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

    Visit the website
    Clinical Trial Services
    • Overview
    • Global Clinical Trial Support
    • Clinical Trial Management
    • Clinical Development Strategy
    • Clinical Trial Design
    • Biostatistics
    • Clinical Sample Management
    • Clinical Research Organization
    Specialty Lab Services
    • Overview
    • Immune Monitoring
    • Flow Cytometry
    • Genomics
    • Tissue & Liquid Biopsy
    • Bioanalytical Testing
    • Cytokine Analysis
    • Biospecimens
    • Sample Processing
    • Global Specimen Transport & Biostorage
    • Contract Research Organization
    • Bioanalysis
    • Neutralizing Antibody (NAb) Assays
    • PBMC Processing
    Data Sciences
    • Overview
    • Biostatistics
    • Clinical Data Management
    • Biometrics
    • QuartzBio
    • Virtual Sample Inventory Management
    Therapeutic Expertise
    • Overview
    • Preclinical Development
    • Early Phase Trials (I-IIa)
    • Late Phase Trials (IIb-III)
    • Oncology and Immuno-Oncology
    • Rare & Orphan Disease
    • Cell & Gene Therapy
    • Neurology
    • COVID-19
    • Autoimmune & Allergy
    • Pediatric
    • Companion Diagnostics
    About Us
    • Our Passion
    • Meet Our People
    • Careers
    • ESG Policy
    • Regulatory Information

    News & Insights
    • Publications
    • Case Studies
    • Thought Leadership
    • News
    • Events
    © 2023 Precision Medicine Group, LLC. All rights reserved. Privacy Policy    GDPR